Congestive Hepatopathy

Fortea, José Ignacio; Puente, Ángela; Cuadrado‐Lavín, Antonio; Huelín, Patrícia; Pellón, Raúl; Sánchez, Francisco José González; Mayorga, Marta; Cagigal, María Luisa; Carrera, Inés; Cobreros, Marina; Crespo, Javier; Fábrega, Emilio

doi:10.3390/ijms21249420

Cited by 49 publications

(48 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The widespread use of heart transplantation (HT) and considerable breakthroughs in medical and surgical treatments have drastically altered the profile of CH patients. As a result, compared to previous reports, cardiac cirrhosis due to noncongenital HF is decreasing, ischemic cardiomyopathy has superseded rheumatic HF as the primary cause of HF, and CH following Fontan surgery is increasing [3].…”

Section: Fig 2 Liver Outcomes Following Heart Transplantmentioning

confidence: 79%

“…Development of cirrhosis and eventually cirrhosis of the liver may occur, with associated risks of liver failure and hepatocellular carcinoma. This risk is likely to increase over the course of the patient's life [3,[8][9][10] (Fig. 2).…”

Section: Fig 2 Liver Outcomes Following Heart Transplantmentioning

confidence: 99%

“…They are commonly divided into three categories based on the role of each organ as the cause or victim of the other: (1) liver disease caused by heart illness; (2) heart disease caused by liver disease (e.g., cirrhotic cardiomyopathy); and (3) systemic diseases affecting both the heart and the liver (e.g., systemic amyloidosis). The former is commonly referred to as "cardiac hepatopathy" [3].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Overview on Cardiac Cirrhosis and Congestive Hepatopathy - A Review

Hussein

Almujil

Banheem

et al. 2021

JPRI

View full text Add to dashboard Cite

Cardiac cirrhosis (congestive hepatopathy) refers to a group of hepatic abnormalities that develop as a result of right-sided heart failure. Cirrhosis of the liver can be induced by any right-sided pathology that leads to right-sided heart failure, which leads to increased venous congestion and pressure in the hepatic sinusoids. Because cardiac cirrhosis might be asymptomatic or diagnosed incorrectly due to other types of liver disease, determining its prevalence is difficult. The underlying heart disease, rather than the hepatic congestion and damage, is usually the cause of death in cardiac cirrhosis. The control of the underlying cardiac disease, as well as the optimization of cardiac output, are the mainstays of congestive hepatopathy treatment. Diuresis can help with hepatic congestion, but it must be used with caution to avoid causing hepatic ischemia. Hemodynamic therapy may be able to reverse the early stages of congestive hepatitis. The widespread use of heart transplantation (HT) and considerable breakthroughs in medical and surgical treatments have drastically altered the profile of CH patients. In this overview we will be looking at the disease cause, epidemiology, diagnosis, and treatment.

show abstract

Section: Fig 2 Liver Outcomes Following Heart Transplantmentioning

confidence: 79%

Section: Fig 2 Liver Outcomes Following Heart Transplantmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Overview on Cardiac Cirrhosis and Congestive Hepatopathy - A Review

Hussein

Almujil

Banheem

et al. 2021

JPRI

View full text Add to dashboard Cite

show abstract

“…One of its main forms is congestive hepatopathy (CH), consisting of venous congestion associated with right-sided HF. The chain of events determined by chronic passive congestion is represented by sinusoidal hypertension, centrilobular fibrosis, cirrhosis, and even carcinogenesis (hepatocellular carcinoma) [ 81 ]. In another study, miR-122, the predominant miRNA in the liver [ 82 ], was indicated to be essential for liver homeostasis, while its loss resulted in promoting liver steatosis, inflammation, fibrosis, and even carcinogenesis [ 82 – 84 ].…”

Section: Personalized Medicine In Heart Failurementioning

confidence: 99%

MicroRNAs as monitoring markers for right-sided heart failure and congestive hepatopathy

Ionescu

Creţoiu

2021

JMedLife

View full text Add to dashboard Cite

The last decades showed a worrying increase in the evolution of cardiovascular diseases towards different stages of heart failure (HF), as a stigma of the western lifestyle. MicroRNAs (miRNAs), non-coding RNAs, which are approximately 22-nucleotide long, were shown to regulate gene expression at the post-transcriptional level and play a role in the pathogenesis and progression of HF. miRNAs research is of high interest nowadays, as these molecules display mechanisms of action that can influence the course of evolution of common chronic diseases, including HF. The potential of post-transcriptional regulation by miRNAs concerning the diagnosis, management, and therapy for HF represents a new promising approach in the accurate assessment of cardiovascular diseases. This review aims to assess the current knowledge of miRNAs in cardiovascular diseases, especially right-sided heart failure and hepatomegaly. Moreover, attention is focused on their role as potential molecular biomarkers and more promising aspects involving miRNAs as future therapeutic targets in the pathophysiology of HF.

show abstract

“…Currently, the commonly used methods for evaluating the severity and prognosis of patients with liver failure are mostly based on the functions of multiple organs themselves. [14][15][16][17] But this method has limitations in terms of accuracy and convenience of application. Hormones play an important role in body metabolism and organ function regulation.…”

Section: Introductionmentioning

confidence: 99%

Cortisol in Peripheral Blood Predicts the Severity and Prognosis in Patients with Liver Failure at 90 Days

Zhang¹,

Li²,

Ding³

et al. 2021

RMHP

View full text Add to dashboard Cite

Objective:To investigate the cortisol level in peripheral blood in evaluating the severity and prognosis of patients with liver failure. Methods: A total of 211 inpatients with liver failure were enrolled in Beijing You 'an Hospital affiliated with Capital Medical University, from September 2018 to January 2020. They were divided into three groups according to the severity of liver failure: early-stage liver failure, medium-stage liver failure and end-stage liver failure. In all patients, peripheral venous blood was gathered to detect the level of peripheral cortisol and related biochemical indexes. Logistic regression was used to screen the risk factors affecting the prognosis of patients at 90 days. A receiver operating curve (ROC) was used to reflect the value of cortisol on the prognosis of patients at 90 days. A model for end-stage liver disease (MELD) was accessed. Results: Among these 211 patients with liver failure, aged from 19 to 70 years, the average level of cortisol was 351.26 ± 129.78 nmol/L for 101 cases with early-stage liver failure, 281.05 ± 81.31 nmol/L for 58 cases with medium-stage liver failure, and 189.21 ± 89.27 nmol/L for 52 cases with end-stage liver failure (P < 0.05). The level of cortisol in the survival group and the non-survival group was 339.26 ± 121.19 nmol/L and 192.71 ± 67.23 nmol/L, respectively (P < 0.05). The results of logistics regression analysis showed that the odds ratio (OR) and 95% confidence intervals (CI) of cortisol were 1.025 and 1.013-1.038 nmol/L (P < 0.05). MELD results showed that patients with higher MELD scores had lower cortisol content. Conclusion:The level of cortisol is correlated with the severity of liver failure and decreases with the aggravation of liver failure, suggesting that the level of cortisol could be used as one of the indicators to evaluate the prognosis in patients with liver failure at 90 days.

show abstract

Congestive Hepatopathy

Cited by 49 publications

References 125 publications

Overview on Cardiac Cirrhosis and Congestive Hepatopathy - A Review

Overview on Cardiac Cirrhosis and Congestive Hepatopathy - A Review

MicroRNAs as monitoring markers for right-sided heart failure and congestive hepatopathy

Cortisol in Peripheral Blood Predicts the Severity and Prognosis in Patients with Liver Failure at 90 Days

Contact Info

Product

Resources

About